Cetero Research, the leading early-stage contract research organization (CRO), today announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical study. This achievement solidifies Cetero's position as the unmatched leader in early-phase clinical development and highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.
"We are very proud of this extraordinary accomplishment, which has been made possible by our dedicated staff and loyal clients," said Troy W. McCall, PhD, Chief Executive Officer of Cetero. "One of the best measures of a CRO's capabilities is its depth and breadth of experience. Cetero can offer clients more efficient clinical studies and assurance of high-quality data on time as a result of having more early-phase experience than any other CRO."
In conducting 20,000 studies over the past 30 years, Cetero has developed considerable experience with normal healthy participants, special populations and patients. Through targeted recruitment strategies and a constantly updated database, Cetero currently delivers a 99 percent on-time recruitment rate.
"Twenty-thousand studies is a significant achievement and truly reflects Cetero's strengths in conducting both traditional clinical trials with normal healthy participants and specialty Phase I and IIa trials with patients," said Alan Copa, PharmD, President, Clinical Operations - Fargo of Cetero. "Cetero's expertise across a wide range of therapeutic areas provides us with insights on drug development strategies in addition to efficient study execution."
New research sheds light on how GLP-1 obesity drugs may change food cravings